Maia Biotechnology Stock Fundamentals
| MAIA Stock | USD 2.09 0.01 0.48% |
MAIA Biotechnology fundamentals help investors to digest information that contributes to MAIA Biotechnology's financial success or failures. It also enables traders to predict the movement of MAIA Stock. The fundamental analysis module provides a way to measure MAIA Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MAIA Biotechnology stock.
At present, MAIA Biotechnology's Total Other Income Expense Net is projected to decrease significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 29 K, whereas Depreciation And Amortization is forecasted to decline to 1.90. MAIA | Select Account or Indicator |
MAIA Biotechnology Company Return On Asset Analysis
MAIA Biotechnology's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current MAIA Biotechnology Return On Asset | -1.07 |
Most of MAIA Biotechnology's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MAIA Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
MAIA Total Assets
Total Assets |
|
Based on the latest financial disclosure, MAIA Biotechnology has a Return On Asset of -1.0711. This is 87.76% lower than that of the Biotechnology sector and 95.46% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
MAIA Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MAIA Biotechnology's current stock value. Our valuation model uses many indicators to compare MAIA Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MAIA Biotechnology competition to find correlations between indicators driving MAIA Biotechnology's intrinsic value. More Info.MAIA Biotechnology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, MAIA Biotechnology's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MAIA Biotechnology's earnings, one of the primary drivers of an investment's value.MAIA Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MAIA Biotechnology's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MAIA Biotechnology could also be used in its relative valuation, which is a method of valuing MAIA Biotechnology by comparing valuation metrics of similar companies.MAIA Biotechnology is currently under evaluation in return on asset category among its peers.
MAIA Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MAIA Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MAIA Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
MAIA Fundamentals
| Return On Equity | -5.6 | ||||
| Return On Asset | -1.07 | ||||
| Current Valuation | 44.25 M | ||||
| Shares Outstanding | 25.33 M | ||||
| Shares Owned By Insiders | 17.49 % | ||||
| Shares Owned By Institutions | 7.50 % | ||||
| Number Of Shares Shorted | 662.41 K | ||||
| Price To Book | 32.71 X | ||||
| EBITDA | (20.18 M) | ||||
| Net Income | (19.77 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 7.09 M | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (13.07 M) | ||||
| Short Ratio | 10.99 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 12.63 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 52.94 M | ||||
| Total Asset | 7.57 M | ||||
| Retained Earnings | (63.98 M) | ||||
| Working Capital | 2.63 M | ||||
| Net Asset | 7.57 M |
About MAIA Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MAIA Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MAIA Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MAIA Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 128 K | 134.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out MAIA Biotechnology Piotroski F Score and MAIA Biotechnology Altman Z Score analysis. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.